- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05534607
Natives Engaged in Alzheimers Research - 'Ike Kupuna (NEAR)
Natives Engaged in Alzheimers Research - 'Ike Kupuna (Elder Wisdom) Project
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Janice K Worthington, MPH
- Phone Number: 8086921023
- Email: ikekupuna@gmail.com
Study Locations
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96813
- Recruiting
- Kula No Na Po'e
-
Contact:
- Adrienne Dillard, PhD
- Phone Number: 808-692-1023
- Email: ikekupuna@gmail.com
-
Honolulu, Hawaii, United States, 96819
- Recruiting
- Kokua Kalihi Valley
-
Contact:
- Sheryl Yoshimura, RD
- Phone Number: 808-692-1023
- Email: ikekupuna@gmail.com
-
Wailuku, Hawaii, United States, 96793
- Recruiting
- Hui No Ke Ola Pono
-
Contact:
- Malia Purdy, PhD
- Phone Number: 808-692-1023
- Email: ikekupuna@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- self-reported Native Hawaiian or other Pacific Islander ancestry;
- ages 50+ but not older than 75 (optimal age range for preventing future dementia in people with cognitive impairment, above 75 is not likely to benefit from this study given their advance age);
- has subjective cognitive impairment (SCI) or mild cognitive impairment (MCI);
- have a diagnosis of hypertension, diabetes, dyslipidemia, or obesity (body-mass-index ≥ 30 kg/m2);
- physically able and willing to engage in moderate physical activity necessary for Hula; and
- physician's approval to participate in moderate physical activity
Exclusion Criteria:
- currently pregnant;
- already actively practicing Hula at least once per week; or
- clinical diagnosis of ADRD (mild to severe); or
- current diagnosed major depressive disorder at moderate or greater stage, or moderate or greater depression on the Center for Epidemiological Studies Depression Scale (CES-D).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention group
The intervention group will immediately receive the Ola Mau i ka Hula intervention after randomization for 12 months.
The intervention program is 8 months with a 4 month self-monitoring period.
|
The first 3 months of the hula-based intervention program was designed and standardized as a culturally-based physical activity (PA) that includes 15 minutes of ADRD education and intervention orientation with 12 weeks of hula lessons. These hula lessons consist of two 60-minute classes per week over 12 weeks. Each hula lesson will consist of 8 participants, providing them with the opportunity to engage-in this social support network. For the remaining 5 months of the Ola Mau i ka Hula Program, hula lessons led by the kumu hula will be reduced to once a month for 60 min. In addition, the intervention group will meet with a community-peer educator weekly over this 5-month period. Each meeting will be 90 minutes in length with 60 minutes of hula practice following the same format as previous classes, and 30 minutes will cover the PILI Lifestyle Plan curriculum and cultural-based cognitive exercises, alternating weekly.
Other Names:
|
|
No Intervention: Wait-list control group
After baseline data collection, participants randomized to the wait-list control arm will not receive the Ola Mau i ka Hula Program while their counterparts who were randomized to the intervention arm are undergoing the intervention program. Thus, they will not be offered the intervention until after the intervention arm is completed and their 12-month follow-up data collection is completed. They will only receive the educational component of the intervention from us during this 12-month period but they will be instructed to continue with their routine medical care as usual. Wait-list control group will be offered the opportunity to receive intervention at the conclusion of 12 month assessment period, regardless of whether they were retained for the full 12 months of data collection. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in participants' systolic blood pressure at each time frame from baseline
Time Frame: 3 months, 8 months, 12 months
|
Vascular risk factor assessed using Omron©HEM-907XL
|
3 months, 8 months, 12 months
|
|
Change in participants' Hemoglobin A1c at each time frame from baseline
Time Frame: 12 months
|
Vascular risk factor assessed using Alere Cholestech LDX® System
|
12 months
|
|
Change in participants' total cholesterol at each time frame from baseline
Time Frame: 3 months, 8 months, 12 months
|
Vascular risk factor assessed using Alere Cholestech LDX® System
|
3 months, 8 months, 12 months
|
|
Change in participants' body mass index at each time frame from baseline
Time Frame: 3 months, 8 months, 12 months
|
Vascular risk factor assessed using Tanita BWB800AS scale
|
3 months, 8 months, 12 months
|
|
Change in participants' Cognitive Change Index score at each time frame from baseline
Time Frame: 3 months, 8 months, 12 months
|
Cognitive function assessed using Cognitive Change Index assessment
|
3 months, 8 months, 12 months
|
|
Change in participants' Number Symbol Coding Test score at each time frame from baseline
Time Frame: 3 months, 8 months, 12 months
|
Cognitive function assessed using Number Symbol Coding Test
|
3 months, 8 months, 12 months
|
|
Change in participants' overall Cognivue score at each time frame from baseline
Time Frame: 3 months, 8 months, 12 months
|
Cognitive function assessed using Cognivue device
|
3 months, 8 months, 12 months
|
|
Change in participants' overall Quick Dementia Rating System score at each time frame from baseline
Time Frame: 3 months, 8 months, 12 months
|
Cognitive function assessed using Quick Dementia Rating System assessment
|
3 months, 8 months, 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Joseph K Kaholokula, PhD, University of Hawaii
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 'Ike Kupuna
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mild Cognitive Impairment
-
Saglik Bilimleri UniversitesiAnkara UniversityRecruitingAmnestic Mild Cognitive Impairment | Amnestic Mild Cognitive DisorderTurkey
-
Masaryk UniversityRecruitingMild Cognitive Impairment (MCI) Amnestic | Lewy Body Disease With Mild Cognitive Impairment | Parkinson's Disease With Mild Cognitive ImpairmentCzechia
-
BaycrestCentre for Aging and Brain Health InnovationUnknownNeurocognitive Disorders | Cognitive Dysfunction | Mental Disorder | Cognitive Impairment, Mild | Cognitive Disorder | Nonamnestic Mild Cognitive ImpairmentCanada
-
Singapore General HospitalSingapore Health ServicesNot yet recruitingMild Cognitive Impairment (MCI) | Mild Cognitive Impairment
-
Xuanwu Hospital, BeijingNot yet recruitingMild Cognitive Impairment (MCI)China
-
The Hong Kong Polytechnic UniversityJohns Hopkins University; The University of Hong Kong; University of ReadingNot yet recruitingMild Cognitive Impairment (MCI)Hong Kong
-
Universidad Complutense de MadridAB Biotics, SANot yet recruitingMild Cognitive Impairment (MCI)Spain
-
University of SheffieldNot yet recruitingMild Cognitive Impairment (MCI)United Kingdom
-
The Hong Kong Polytechnic UniversityRecruitingMild Cognitive Impairment (MCI)Hong Kong
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.TerminatedMild Cognitive Impairment (MCI)Taiwan